Barely Significant

Excerpts

3,685 sentences · 1 filter applied

The EMERALD-1 trial showed that the addition of durvalumab (anti-PD-L1) and bevacizumab to TACE significantly extended progression-free survival compared with TACE alone (15.0 versus 8.2 months; HR 0.77, p = 0.032), successfully meeting the primary endpoint and demonstrating a strong trend toward overall survival improvement [ 93 ].
In particular, our (near-significant) results regarding the analysis of adjuvant systemic treatment, as well as those of the separate analysis of subcohorts with different counts of treated metastases, could both benefit from larger sample sizes, in order to clearly define the potential influence of these factors on PFS and OS.